SKYX Platforms Corp ( $SKYX ) Smart Ceiling Plugs

SKYX Platforms is trying to turn a seemingly boring standard – the ceiling light socket – into a plug-and-play infrastructure layer for lighting and smart-home devices, backed by dozens of patents, distribution partnerships and collaborations with larger technology players. Revenue growth is strong and the product vision is ambitious, but the business is still loss-making and depends on external capital, disciplined execution and a long time horizon.

Americas Gold and Silver Corp ( $USAS ) Record production and the 2026 Inflection

Americas Gold and Silver Corporation (NYSE American: USAS / TSX: USA) is a Toronto-based junior silver producer with three active mining assets in the United States and Mexico. After years of restructuring, the company has entered a genuine inflection phase: FY2025 silver production reached a record 2.65 million ounces (+52% YoY), the Q3 FY2025 adjusted EBITDA turned positive for the first time, and analyst consensus revenue forecasts for FY2026 have been revised up by +265% to $383 million.

Mannkind Corp ( $MNKD ) after the Tresmi shock

A first full-scope look at MannKind after Q4 2025 results and United Therapeutics’ new soft-mist treprostinil product (“Tresmi”), with focus on revenue mix, 2026 catalysts, balance sheet, insider and institutional positioning, analyst expectations and retail sentiment around the latest 35–40% drawdown.

BlackSky Technology Inc ( $BKSY )

Q4 2025 delivered record quarterly revenue and a sharply narrower net loss, while management doubled down on Gen-3 very-high-resolution satellites and real-time AI analytics. At the same time, the new $100 million at-the-market equity program changed the risk-reward for equity holders. This report puts the latest numbers, the 2026 guidance and the capital structure into context, with a focus on how BKSY fits into the broader “Golden Dome” and space-defence narrative we follow at Merlintrader.

Novavax ( $NVAX ) Q4 2025 and the Matrix-M platform

Q4 2025 finally shows what the long Novavax story on Merlintrader was pointing to: revenue above 1.1 billion dollars for the year, a clean return to GAAP profitability in the quarter, and a 2026–2028 roadmap where Sanofi, Pfizer and other partners, not Novavax alone, carry most of the execution risk around Matrix-M.

Biocryst Pharmaceuticals Inc ( $BCRX )Feb26 2026

FY 2025 marks an inflection point for BioCryst. After years of heavy investment to launch ORLADEYO, the company has finally delivered a clearly profitable year: total revenue reached roughly 875M USD in 2025, versus ~451M USD in 2024, and the P&L flipped from a small operating loss to more than 340M USD of operating profit. The key driver was ORLADEYO net revenue of about 602M USD, up nearly 40% year on year, supported by strong new-patient growth in the U.S. and a better-than-guided performance overall.

Teva- Pharmaceutical Industries ( $TEVA ) Feb26 2026

As of late February 2026, Teva combines a still-massive generics footprint with a focused innovative portfolio in CNS and immunology. After a lost decade of litigation, write-downs and restructuring, the company is now delivering mid-single-digit top-line growth, expanding non-GAAP margins and generating roughly $2.4B of free cash flow per year while steadily reducing debt.

Eton Pharmaceuticals Inc ( $ETON) Feb25 FDA OK

The U.S. Food and Drug Administration has approved DESMODA (desmopressin acetate) oral solution for the treatment of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), in adults and pediatric patients. This is the first and only FDA-approved ready-to-use oral solution of desmopressin, a meaningful upgrade in day-to-day management of this rare water-balance disorder.

Geron Corp ( $GERN ) Good Year, Tough Quarter Feb 2026

The first full commercial year of RYTELO brought ~$184M in revenue and a growing base of prescribing centers, but a softer Q4 versus expectations and unchanged 2026 guidance triggered a sharp pullback in the stock. Here is what actually happened, why the market reacted this way, and how it fits into the long-term thesis we’ve been following on Merlintrader.

Rocket Lab and DART AE($RKLB) The night Australia aims for its first hydrogen scramjet flight (Updated feb26)

On many launch days at Wallops, you could drive past Launch Complex 2 and, at a glance, not realise that a rocket is waiting. The Atlantic haze flattens the horizon, the gantry is half-hidden in mist and sodium lights, and only the traffic at the gate and the rhythm of the countdown clocks betray that something is about to happen. Today, that something is a little different from the usual satellite run.